NodThera rebrands as Rezera and targets Phase 3 trial in 2027
read at Endpoints ↗Neutral
NodThera, a biotech focused on the NLRP3 inflammatory pathway for about ten years, announced a strategic shift.
The company said it will rebrand itself as Rezera and is preparing to launch a pivotal Phase 3 clinical trial in 2027.
The move reflects the company's continued development of anti‑inflammatory therapies targeting NLRP3, aiming to advance its lead program toward potential market approval.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand”
read at Endpoints ↗83 words · retrieved Sep 9
comments(0)
5-min edit window · permanent after that